← All organizations
Highest phase reached
Phase 4
First clinical trial
Sep 9, 2020First marketed drug
Jul 24, 2023First NDA
Jul 24, 2023Last known activity
Dec 31, 2023
Timeline
Drugs by trial phase (2 distinct, 10 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Indications
Studied for
Marketed drugs (1)
Recent trials (15)
- NCT06182358Lead sponsorPhase 4Dec 31, 2023
- NCT06054217Lead sponsorPhase 2Aug 1, 2023
- NCT05838170Lead sponsorPhase 2Mar 1, 2023
- NCT05838170Study directorPhase 2Mar 1, 2023
- NCT05720364Study directorPhase 1Jan 19, 2023
- NCT05720364Lead sponsorPhase 1Jan 19, 2023
- NCT05454956Lead sponsorPhase 2Aug 3, 2022
- NCT05387083Lead sponsorPhase 2Jul 29, 2022
- NCT05387083Study directorPhase 2Jul 29, 2022
- NCT05138796Lead sponsorPhase 1May 6, 2021
- NCT05138796Study directorPhase 1May 6, 2021
- NCT04784091Lead sponsorPhase 3Apr 29, 2021
- NCT05138861Lead sponsorPhase 1Feb 9, 2021
- NCT05138861Study directorPhase 1Feb 9, 2021
- NCT04475432Lead sponsorPhase 2/Phase 3Sep 9, 2020
Details
- Founded
- Irvine, CA, US Jun 1, 2016
- First NDA
- Jul 24, 2023
- Last known activity
- Dec 31, 2023